APA (7th ed.) Citation

KER, S., KW, P., JS, P., AJ, W., CA, S., JB, A., . . . MS, B. (2023). A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: Safety, efficacy, and T cell responses. Frontiers in immunology, 14, 1279387. https://doi.org/10.3389/fimmu.2023.1279387

Chicago Style (17th ed.) Citation

KER, Smith, et al. "A Phase I Oncolytic Virus Trial with Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 Administered Intratumorally and Intravenously in Uveal Melanoma: Safety, Efficacy, and T Cell Responses." Frontiers in Immunology 14 (2023): 1279387. https://doi.org/10.3389/fimmu.2023.1279387.

MLA (9th ed.) Citation

KER, Smith, et al. "A Phase I Oncolytic Virus Trial with Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 Administered Intratumorally and Intravenously in Uveal Melanoma: Safety, Efficacy, and T Cell Responses." Frontiers in Immunology, vol. 14, 2023, p. 1279387, https://doi.org/10.3389/fimmu.2023.1279387.